PMID- 35079671
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2472-1972 (Electronic)
IS  - 2472-1972 (Linking)
VI  - 6
IP  - 2
DP  - 2022 Feb 1
TI  - MEN1 Surveillance Guidelines: Time to (Re)Think?
PG  - bvac001
LID - 10.1210/jendso/bvac001 [doi]
LID - bvac001
AB  - Clinical practice guidelines for patients with multiple endocrine neoplasia type 
      1 (MEN1) recommend a variety of surveillance options. Given progress over the 
      past decade in this area, it is timely to evaluate their ongoing utility. MEN1 is 
      characterized by the development of synchronous or asynchronous tumors affecting 
      a multitude of endocrine and nonendocrine tissues, resulting in premature 
      morbidity and mortality, such that the rationale for undertaking surveillance 
      screening in at-risk individuals appears robust. Current guidelines recommend an 
      intensive regimen of clinical, biochemical, and radiological surveillance 
      commencing in early childhood for those with a clinical or genetic diagnosis of 
      MEN1, with the aim of early tumor detection and treatment. Although it is 
      tempting to assume that such screening results in patient benefits and improved 
      outcomes, the lack of a strong evidence base for several aspects of MEN1 care, 
      and the potential for iatrogenic harms related to screening tests or 
      interventions of unproven benefit, make such assumptions potentially unsound. 
      Furthermore, the psychological as well as economic burdens of intensive screening 
      remain largely unstudied. Although screening undoubtedly constitutes an important 
      component of MEN1 patient care, this perspective aims to highlight some of the 
      current uncertainties and challenges related to existing MEN1 guidelines with a 
      particular focus on the role of screening for presymptomatic tumors. Looking 
      forward, a screening approach that acknowledges these limitations and 
      uncertainties and places the patient at the heart of the decision-making process 
      is advocated.
CI  - (c) The Author(s) 2022. Published by Oxford University Press on behalf of the 
      Endocrine Society.
FAU - Newey, Paul J
AU  - Newey PJ
AUID- ORCID: 0000-0003-4414-0278
AD  - Division of Molecular and Clinical Medicine, Ninewells Hospital & Medical School, 
      University of Dundee, Dundee DD2 1UB, Scotland, UK.
FAU - Newell-Price, John
AU  - Newell-Price J
AD  - Department of Oncology and Metabolism, The Medical School, University of 
      Sheffield, Sheffield S10 2RX, UK.
LA  - eng
GR  - SCAF/15/01/CSO_/Chief Scientist Office/United Kingdom
PT  - Journal Article
PT  - Review
DEP - 20220111
PL  - United States
TA  - J Endocr Soc
JT  - Journal of the Endocrine Society
JID - 101697997
PMC - PMC8783614
OTO - NOTNLM
OT  - MEN1
OT  - bronchial neuroendocrine tumor
OT  - genetic testing
OT  - multiple endocrine neoplasia type 1
OT  - pancreatic neuroendocrine tumor
OT  - screening
OT  - surveillance
OT  - thymic
EDAT- 2022/01/27 06:00
MHDA- 2022/01/27 06:01
PMCR- 2022/01/11
CRDT- 2022/01/26 05:31
PHST- 2021/10/09 00:00 [received]
PHST- 2022/01/26 05:31 [entrez]
PHST- 2022/01/27 06:00 [pubmed]
PHST- 2022/01/27 06:01 [medline]
PHST- 2022/01/11 00:00 [pmc-release]
AID - bvac001 [pii]
AID - 10.1210/jendso/bvac001 [doi]
PST - epublish
SO  - J Endocr Soc. 2022 Jan 11;6(2):bvac001. doi: 10.1210/jendso/bvac001. eCollection 
      2022 Feb 1.